Economic evaluation of a 100% whey-based partially hydrolyzed infant formula in the prevention of atopic dermatitis among Swiss children

Journal of Medical Economics

Volumn 15, Issue 2, 2012, Pages 378-393

  Iskedjian, Michael ^a,b,c   Belli, Dominique ^d   Farah, Bechara ^a   Navarro, Vincent ^b   Detzel, Patrick ^e  

^a PharmIdeas Research and Consulting Inc   (Canada)

^b PharmIdeas Europe SAS   (France)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d Hopital des Enfants Hopitaux universitaires de Geneve   (Switzerland)

^e NESTLÉ RESEARCH CENTER   (Switzerland)

Author keywords

Allergy; Atopic dermatitis; Cost effectiveness analysis; Economic; Infant formula; Infant nutrition; Prevention

Indexed keywords

ALFARE; ALTHERA; APTAMIL 1; BEBA HA; BETAMETHASONE DIPROPIONATE; CORTICOSTEROID; COW AND GATE PEPTI JUNIOR; DIPROLENE CREME; DIPROSONE CREME; ELOCOM CREME; EMOLLIENT AGENT; EXCIPIAL HYDROLOTION; EXCIPIAL LIPOLOTION; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE ACEPONATE; MILK PROTEIN; MOMETASONE FUROATE; NAN HA; NEOCATE; NITRAMIGEN; PIMECROLIMUS; PROFYLAC; TACROLIMUS; UNCLASSIFIED DRUG;

ARTICLE; ARTIFICIAL MILK; ATOPIC DERMATITIS; CHILD; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; ECONOMIC EVALUATION; HEALTH CARE COST; HEALTH CARE UTILIZATION; HIGH RISK POPULATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MILK; NEWBORN; OUTCOME ASSESSMENT; PRESCHOOL CHILD; SENSITIVITY ANALYSIS; STATISTICAL MODEL; SWITZERLAND; WHEY; WHEY BASED PARTIALLY HYDROLYZED INFANT FORMULA;

CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; DERMATITIS, ATOPIC; DIETARY PROTEINS; ECONOMICS, PHARMACEUTICAL; HEALTH RESOURCES; HUMANS; INFANT; INFANT FORMULA; MILK HYPERSENSITIVITY; MILK PROTEINS; MODELS, ECONOMIC; OUTCOME ASSESSMENT (HEALTH CARE); SENSITIVITY AND SPECIFICITY; SWITZERLAND;

EID: 84858129347     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2011.650521     Document Type: Article

References (38)

1. Spergel J, Paller A. Atopic dermatitis and the atopic march. J Allergy Clin Immunol 2003;112:S118-27 (Pubitemid 37550028)
2. Asher M, Montefort S, Bjö rksté n B, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC phases one and three repeat multicountry cross-sectional surveys. Lancet 2006;368:733-43 (Pubitemid 44279052)
3. Schulz Larsen F, Hanifin J. Epidemiology of atopic dermatitis. Immunol Allergy Clin North Am 2002;22:1-24 (Pubitemid 34137417)
4. Bergmann R, Edenharter G, Bergmann K, et al. Atopic dermatitis in early infancy predicts allergic airway disease at 5 years. Clin Exp Allergy 1998;28: 965-70 (Pubitemid 28401835)
5. Halken S. Allergy Review Series VI: the immunology of fetuses and infants. The lessons of noninterventional and interventional prospective studies on the development of atopic disease during childhood. Allergy 2000;55: 793-802 (Pubitemid 30643905)
6. Exl B-M. A review of recent developments in the use of moderately hydrolyzed whey formulae in infant nutrition. Nutr Res 2001;21:355-79 (Pubitemid 32222280)
7. von Berg A, Koletzko S, Filipiak-Pittroff B, et al. The effect of hydrolyzed cow's milk formula for allergy prevention in the first year of life: The German Infant Nutritional Intervention Study, a randomized double-blind trial. J Allergy Clin Immunol 2003;111:533-40 (Pubitemid 36337874)
8. Baehler P, Baenziger O, Belli D, et al. Empfehlungen für die Sä uglingsernä hrung 2009. Paediatrica 2009;20:13-5
9. Lasarte Velillas J. Recomendaciones para la lactancia materna. Comité de Lactancia Materna de la Asociació n Españ ola de Pediatŕa. 2011;1-6 http://www.aeped.es/sites/default/files/lacmat- espanol.pdf [Last Accessed: December 23, 2011]
10. Muche-Borowski C, Kopp M, Reese I, et al. Allergieprävention. AWMF Guideline Register 061/16, 2009
11. Socié té Franç aise de Dermatologie. Prise en charge de la dermatite atopique de l'enfant. Texte des recommandations. Ann Dermatol Vé né ré ol 2005;132:1S9-1S18
12. World Health Organization and United Nations Children's Fund. Global strategy for infant and young child feeding. Geneva: NLM Classification: WS 120, 2003
13. World Health Organization. World Health Organization's recommendations on breasfeeding. Available at: http://www.who.int/topics/breastfeeding/en. Accessed February 9, 2010
14. von Berg A, Filipiak-Pittroff B, Krämer U, et al. Preventative effect of hydrolyzed formulas persists until age 6 years: long-term results from the German Infant Nutritional Intervention Study (GINI). J Allergy Clin Immunol 2008;121: 1442-7 (Pubitemid 351787357)
15. von Berg A, Koletzko S, Filipiak-Pittroff B, et al. Certian hydrolyzed formulas reduce the incidence of atopic dermatitis but not that of asthma: three-year results of the German Infant Nutritional Intervention Study. J Allergy Clin Immunol 2007;119:718-25 (Pubitemid 46335815)
16. Szajewska H, Horvath A. Meta-analysis of the evidence for a partially hydrolyzed 100% whey formula for the prevention of allergic diseases. Curr Med Res Opin 2010;26:423-37
17. Alexander D, Cabana M. Partially hydrolyzed 100% whey protein infant formula and reduced risk of atopic dermatitis: a meta-analysis. J Pediatr Gastroenterol Nutr 2010;50:422-30
18. Lewis-Jones S. Quality of life and childhood atopic dermatitis: the misery of living with childhood eczema. Int J Clin Pract 2006;60:984-92 (Pubitemid 44082290)
19. Kemp A. Cost of illness of atopic dermatitis in children. A societal perspective. Pharmaco Economics 2003;21:105-13 (Pubitemid 36127006)
20. Ricci G, Bendandi B, Pagliara L, et al. Atopic dermatitis in Italian children: evaluation of its economic impact. JPediatr Health Care 2006; 20:312-5
21. Gieler U, Hohmann M, Niemeier V, et al. Cost evaluation in atopic eczema. J Dermatol Treat 1999;10:S15-S20 (Pubitemid 29149890)
22. Weinmann S, Kamtsiuris P, Wickman H, et al. The costs of atopy and asthma in children: assessment of direct costs and their determinants in a birth cohort. Pediatr Allergy Immunol 2003;14:18-26 (Pubitemid 36603985)
23. Iskedjian M, Dupont C, Kanny G, et al. Economic evaluation of a 100% whey-based, partially hydrolyzed formula in the prevention of atopic dermatitis among French children. Curr Med Res Opin 2010;26:2607-26
24. Iskedjian M, Szajewska H, Spieldenner J, et al. Extension of a meta-analysis of the evidence for a partially hydrolyzed 100%-whey formula in theprevention of atopic dermatitis: brief research report. Curr Med Res Opin 2010;26:2599-606
25. Office Fé dé ral des Statistiques. La population de la Suisse 2009. Neuchâ tel: Office Fé dé ral des Statistiques, Report Number: 349-0900, 2010
26. Merten S, Dratva J, Ackermann-Liebrich U. Swiss Federal Office of Public Health. Infant feeding during the first 9 months-Swiss National Study 2003. Berne: 2005
27. Swiss Life Tables 1998/2003. Office fé dé ral de la statistique. Available at: http://www.bfs.admin.ch/bfsportal/en/index/themen/01/ 02/blank/dos/la-mortalite-en-suisse/tabl01.html. Accessed March 1, 2011
28. Compendium Suisse des Mé dicaments. Document. Documed. Available at: http://www.documed.ch/fr/index.php. Accessed March 1, 2011
29. Office fé dé ral de la statistique. Gross activity rate (total population) in 2009. Available at: http://www.bfs.admin.ch/bfs/portal/en/ index/themen/03/02/blank/key/erwerbsquote.html Accessed March 1, 2011
30. International Labour Organization. Hours of work per week by economic activity in Switzerland in 2008 (Table 4A). Available at: http://laborsta.ilo. org. Accessed March 29, 2011
31. International Labour Organization. Wages by economic activity in Germany in 2008 (Table 5A). Available at: http://laborsta.ilo.org. Accessed March 29, 2011
32. TPG (Transports Publics Genè vois). Cost of public transportation in Geneva. Available at: http://www.tpg.ch/fr/titres-de-transport/index.php. Accessed March 1, 2011
33. Genè ve Tourisme. Cost of taxi in Geneva.Available at: http://www.genevetourisme. ch/?rubrique1/40000000415. Accessed March 1, 2011
34. Drummond M, Sculpher M, Torrance G, et al. Methods for the economic evaluation of health care programmes. 3rd edn. Oxford, UK: Oxford University Press, 2006
35. Swiss Federal Social Insurance Office. Manual for the standardization of clinical and economic evaluation of medical technology (1998 draft). Available at: http://www.ispor.org/PEguidelines/countrydet.asp?c1/425&t1/41. Accessed May 3, 2011
36. Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. Oxford, UK: Oxford University Press, 2008
37. Pitt M, Garside R, Stein K. A cost-utility analysis of pimecrolimus vs. topical corticosteroids and emollients for the treatment of mild and moderate atopic eczema. Br J Dermatol 2006;154:1137-46 (Pubitemid 43727397)
38. Coyle D, Barbeau M. Cost effectiveness of elidel in the management of patients with atopic dermatitis in Canada. J Cutan Med Surg 2004;8: 405-10 (Pubitemid 41414108)